Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
1,334 total articles
Disc Medicine Chief Executive John D. Quisel sold 13,264 shares on February 17, 2026, at $62.86 per share, generating proceeds of $833,775 to satisfy tax withholding tied to vesting restricted stock units. The company is simultaneously navigating a regulatory setback for its erythropoietic protoporphyria treatment, bitopertin, after the FDA issued …
Pulse Biosciences, Inc. (NASDAQ: PLSE) reported that Chief Commercial Officer Kevin Patrick Danahy sold 60,000 shares of company stock between February 12 and February 17, 2026, generating $1.41 million. The transactions, executed under a Rule 10b5-1 trading plan adopted May 14, 2025, were carried out at weighted average prices between $23.37 and $…
Ocular Therapeutix Chief Strategy Officer Sanjay Nayak sold 10,348 shares of common stock on February 12, 2026, in a filing that shows the transaction was executed to satisfy tax withholding tied to vested restricted stock units. The sale, executed at a weighted average price of $9.04 for a total of $93,545, comes as the company reported positive P…
Ocular Therapeutix COO Donald Notman sold 11,446 shares on February 12, 2026, for $103,471 at a weighted average price of $9.04. The sale left him with 366,356 shares. The transaction coincides with the company reporting a Phase 3 superiority result for its investigational wet age-related macular degeneration treatment AXPAXLI, a reaffirmation of a…
Nadia Waheed, Chief Medical Officer at Ocular Therapeutix, sold 7,863 shares on February 12, 2026 to satisfy tax withholding tied to vested restricted stock units, leaving her with 318,417 shares. The transaction coincides with the company’s disclosure of positive Phase 3 SOL-1 results for AXPAXLI in wet age-related macular degeneration, an RBC Cap…
Ocular Therapeutix Executive Chairman, President and CEO Pravin Dugel sold 124,882 shares on February 12, 2026, in a transaction totaling $1.13 million to satisfy tax obligations tied to restricted stock unit vesting. The company also disclosed a successful Phase 3 superiority outcome for its wet age-related macular degeneration candidate AXPAXLI, …
Nicole Murphy, Head of Pharmaceutical Operations and Technology at Biogen (BIIB), purchased three shares of the company's common stock on February 12, 2026, at $195.035 per share for a total of $585. The purchase was recorded on a Form 4 filing and follows strong recent market performance for Biogen, which trades near its 52-week high. Murphy also …
On December 18, 2025, Samsara Opportunity Fund, L.P. bought 479,847 shares of Kalaris Therapeutics at $10.42 per share in a privately negotiated transaction valued at $5,000,005. The trade raises Samsara Opportunity Fund’s direct stake to 1,979,847 shares and follows a disposition from Samsara BioCapital, L.P., which now holds 10,968,234 shares. Ka…
Equinix Inc.'s Chief Financial Officer, Keith D. Taylor, sold 2,000 shares on February 12, 2026, for $956.44 each, generating roughly $1.9 million. The company has issued 2026 revenue and adjusted funds from operations per share guidance that exceeded Wall Street expectations, reported record bookings and monthly recurring revenue growth, and promp…
Saira Ramasastry, a director at Mirum Pharmaceuticals (MIRM), sold 2,000 shares on February 13, 2026, under a prearranged Rule 10b5-1 plan and exercised options for 2,000 shares the same day. The stock is trading close to its 52-week high after Mirum reported preliminary 2025 product sales that exceeded guidance, projected significant growth for 20…
Envoy Medical Interim Chief Financial Officer Robert Potashnick purchased 212,500 shares of Class A Common Stock for $85,000 and acquired warrants to buy an additional 340,000 shares. The company also reported reaching the midway point in enrollment for its pivotal study of the Acclaim cochlear implant and disclosed issuance of an Australian patent…
Dawn Christine Maroney, president of Alignment Healthcare, sold 30,000 shares on February 17, 2026, for a total of $618,990 under a Rule 10b5-1 plan. The transaction occurred at prices between $20.05 and $20.99, near the quoted share price of $20.59. The company is set to report earnings on February 26, and analysts have recently lifted price targe…
Alnylam Pharmaceuticals Executive Vice President and Chief R&D Officer Pushkal Garg sold 2,242 shares on February 13, 2026, to satisfy minimum statutory tax withholding tied to the vesting of performance-based stock units. The transaction totaled $695,201 at a weighted average price of $310.0808. The filing outlines the PSU vesting, Garg’s post-sal…
Monolithic Power Systems Inc. Chief Executive Officer Michael Hsing sold 31,260 shares on February 12, 2026, for about $38.6 million under a Rule 10b5-1 plan. The transactions occurred at prices between $1,155.71 and $1,217.12, while the stock trades near its 52-week high of $1,250. The company reported robust fourth-quarter 2025 results and saw se…
Avidbank Holdings Inc. director Mike Rosinus sold 5,076 shares on February 17, 2026, at $30.172 per share for a total of $153,153. After the transaction Rosinus holds 16,680 shares directly and 183,122 shares indirectly. Separately, the company reported fourth-quarter fiscal 2025 results with EPS of $0.65 versus an analyst forecast of $0.76, and re…
Alnylam Pharmaceuticals Chief Executive Officer Yvonne Greenstreet sold 6,958 shares of common stock on February 13, 2026, in a transaction totaling about $2.16 million to satisfy minimum statutory tax withholding tied to a performance-based stock unit award that vested the prior day. The company reported mixed fourth-quarter 2025 results, with an …
AppTech Payments director Albert L. Lord purchased 4,200 shares on February 12, 2026, at an average price of $0.3964 per share, totaling $1,664. Separately, the company amended a $360,000 Senior Unsecured Convertible Promissory Note with Eleven 11 Management LLC, altering the maturity and staging principal repayments with outstanding interest due a…
David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, sold 417 shares of company stock on February 17, 2026, under a Rule 10b5-1 trading plan and simultaneously exercised options to acquire an equal number of shares. The transactions leave Rodman with 44,089 directly held shares. Mineralys has seen a substantial share-price gain ove…
Reid Alan McWilliams, Executive Vice President, Global Human Resources at Sanmina Corp, sold 3,500 shares on February 13, 2026, for $148.45 per share, realizing $519,574. After the sale he retains 33,981 shares. Separately, Sanmina reported first-quarter 2026 results with EPS of $2.38 versus $2.14 expected and revenue of $3.19 billion, 3.24% above …
HA Sustainable Infrastructure Capital director Jeffrey Eckel sold $5.2 million worth of company stock on February 17, 2026, in two separate transactions. The trades occurred as HASI traded close to its 52-week high and after the company reported fourth-quarter 2025 results that beat expectations. An analyst lift and dividend details round out recen…
Andrew Benjamin Walz, President, DM&C at Chevron Corp (NYSE: CVX), sold 666 shares of common stock on February 12, 2026, realizing $122,144. The transaction followed by his continued direct and indirect holdings coincides with company moves into the Sirte Basin, a major offshore contract award with Subsea 7, and an analyst upgrade that highlights C…
Guidewire Software Chief Executive Officer Michael George Rosenbaum sold 1,200 shares on February 17, 2026, netting $152,400 in an automated transaction under a 10b5-1 plan. The sale occurred while the stock traded close to its 52-week low, even as the company announced a new $500 million repurchase program and received analyst upgrades following f…
Andrew R. Harrison, Executive Vice President and Chief Commercial Officer of Alaska Air Group, sold 14,500 shares on February 13, 2026, at an average price of $54.8112 per share for roughly $794,762, following the conversion of restricted stock units into common shares. Additional share disposals to cover tax obligations and the company's recen…
Joby Aviation's Chief Legal Officer and Corporate Secretary, Kate Dehoff, sold 8,539 shares of common stock on February 13, 2026, at $9.88 per share to satisfy tax obligations tied to the settlement of restricted stock units. The filing shows she had exercised options on 19,047 shares the prior day at no cash exercise cost. The insider move comes a…
Joby Aviation Chief Executive and Chief Architect JoeBen Bevirt disposed of roughly $5.8 million of company stock through multiple transactions executed under a pre-arranged 10b5-1 plan, while the company completed concurrent public offerings that raised roughly $1.2 billion and moved to expand manufacturing capacity with a new Dayton, Ohio facilit…
